* |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this
form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Phase4 Partners Limited
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
England and Wales
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares1
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares1
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares1
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%2
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
OO |
|
|
|||
|
|
1 |
Represents shares held by Phase4 Ventures III GP LP (“Phase4 GPLP”) in its capacity as general partner of Phase4 Ventures III LP (“Phase4 III”). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited (“Phase4
GP”). Phase4 GP has appointed Phase4 Partners Limited (“Phase4 Partners”) to act as the manager of Phase4 III. Phase4 Partners ultimately exercises voting and investment power over the securities held by Phase4 GPLP. Dr. Alastair McKinnon, Denise
Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Phase4 Partners, Phase4 GP, Phase4 GPLP and Phase4 III may each be deemed to have sole voting and dispositive power over the shares and Dr. McKinnon, Dr.
Scots-Knight and Mr. Sermon may each be deemed to have shared voting and dispositive power over the shares.
|
2 |
The percentage ownership was calculated based on 11,897,146 shares of common stock outstanding as of the March 1, 2018, as disclosed in the Annual Report on Form 10-K for
the fiscal year ended December 31, 2018 filed by Albireo Pharma, Inc. (the “Issuer”) with the Securities and Exchange Commission on March 27, 2018.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Phase4 Ventures III LP
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
England and Wales
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares3
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares3
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares3
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%4
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
PN
|
|
|
|||
|
|
3 |
See footnote 1.
|
4 |
See footnote 2.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Phase4 Ventures III GP LP
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Scotland
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares5
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares5
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares5
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%6
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
PN
|
|
|
|||
|
|
5 |
See footnote 1.
|
6 |
See footnote 2.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Phase4 Ventures III General Partner Limited
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Scotland
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares7
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares7
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares7
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%8
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
OO
|
|
|
|||
|
|
7 |
See footnote 1.
|
8 |
See footnote 2.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Dr. Alastair McKinnon
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
United Kingdom
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares |
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares9
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares9
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares9
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%10
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
IN
|
|
|
|||
|
|
9 |
See footnote 1.
|
10 |
See footnote 2.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Denise Scots-Knight, Ph.D.
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
United Kingdom
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares11
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares11
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares11
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
0%12 |
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
IN
|
|
|
|||
|
|
11 |
See footnote 1.
|
12 |
See footnote 2.
|
CUSIP No. 01345P 106
|
Schedule 13D
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
Charles Sermon
|
|
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☒ (joint filers)
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS
|
|
|
||
OO
|
|
|
|||
|
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
United Kingdom
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
0 shares
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0 shares13
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
0 shares
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0 shares13
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0 shares13
|
|
|
|||
|
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
%14
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON
|
|
|
||
IN
|
|
|
|||
|
|
13 |
See footnote 1.
|
14 |
See footnote 2.
|
Item 5. |
Interest in Securities of the Issuer.
|
Phase4 Partners
|
0 shares
|
Phase4 III
|
0 shares
|
Phase4 GPLP
|
0 shares
|
Phase4 GP
|
0 shares
|
Dr. Alastair McKinnon
|
0 shares
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
Charles Sermon
|
0 shares
|
Phase4 Partners Limited
|
0%
|
Phase4 Ventures III LP
|
0%
|
Phase4 Ventures III GP LP
|
0%
|
Phase4 Ventures III General Partner Limited
|
0%
|
Dr. Alastair McKinnon
|
0%
|
Dr. Denise Scots-Knight
|
0%
|
Charles Sermon
|
0%
|
(i) |
Sole power to vote or to direct the vote:
|
Phase4 Partners
|
0 shares
|
Phase4 III
|
0 shares
|
Phase4 GPLP
|
0 shares
|
Phase4 GP
|
0 shares
|
Dr. Alastair McKinnon
|
0 shares
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
Charles Sermon
|
0 shares
|
(ii) |
Shared power to vote or to direct the vote:
|
Phase4 Partners
|
0 shares
|
Phase4 III
|
0 shares
|
Phase4 GPLP
|
0 shares
|
Phase4 GP
|
0 shares
|
Dr. Alastair McKinnon
|
0 shares
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
Charles Sermon
|
0 shares
|
(iii) |
Sole power to dispose or to direct the disposition of:
|
Phase4 Partners
|
0 shares
|
Phase4 III
|
0 shares
|
Phase4 GPLP
|
0 shares
|
Phase4 GP
|
0 shares
|
Dr. Alastair McKinnon
|
0 shares
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
Charles Sermon
|
0 shares
|
(iv) |
Shared power to dispose or to direct the disposition of:
|
Phase4 Partners
|
0 shares
|
Phase4 III
|
0 shares
|
Phase4 GPLP
|
0 shares
|
Phase4 GP
|
0 shares
|
Dr. Alastair McKinnon
|
0 shares
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
Charles Sermon
|
0 shares
|
Date
|
Number of Shares of
Common Stock
|
Price per Share*
|
Price Range
|
|
01/31/18
|
1,200
|
35.1000
|
$35.00
|
$35.18
|
02/01/18
|
2,802
|
35.1790
|
$35.00
|
$35.68
|
02/02/18
|
1,504
|
35.0057
|
$35.00
|
$35.10
|
02/05/18
|
4,397
|
35.2435
|
$35.00
|
$35.97
|
02/05/18
|
100
|
36.2400
|
$36.24
|
$36.24
|
02/06/18
|
947
|
35.0000
|
$35.00
|
$35.00
|
02/07/18
|
10,900
|
35.1653
|
$34.50
|
$35.50
|
02/07/18
|
3,800
|
35.7621
|
$35.51
|
$36.00
|
02/08/18
|
3,265
|
34.9687
|
$34.50
|
$35.46
|
02/08/18
|
6,735
|
36.1012
|
$35.88
|
$36.25
|
02/09/18
|
2,366
|
34.5767
|
$34.50
|
$34.66
|
02/12/18
|
3,954
|
35.1117
|
$34.55
|
$35.55
|
02/12/18
|
16,046
|
36.1772
|
$35.81
|
$36.76
|
02/13/18
|
5,068
|
35.2218
|
$34.73
|
$35.73
|
02/13/18
|
4,932
|
36.0705
|
$35.74
|
$36.36
|
02/14/18
|
9,900
|
35.6986
|
$35.02
|
$36.00
|
02/14/18
|
100
|
36.1500
|
$36.15
|
$36.15
|
02/15/18
|
9,700
|
35.6332
|
$35.16
|
$36.18
|
02/15/18
|
300
|
36.1767
|
$36.17
|
$36.18
|
02/16/18
|
5,984
|
34.8840
|
$34.50
|
$35.44
|
02/20/18
|
5,617
|
34.7734
|
$34.50
|
$35.21
|
02/21/18
|
1,260
|
34.5998
|
$34.50
|
$34.87
|
02/26/18
|
4,121
|
34.7987
|
$34.50
|
$35.02
|
02/27/18
|
92
|
34.5000
|
$34.50
|
$34.50
|
02/28/18
|
200
|
34.5200
|
$34.50
|
$34.54
|
03/02/18
|
12,405
|
34.8597
|
$34.50
|
$35.44
|
03/05/18
|
5,053
|
34.7777
|
$34.50
|
$35.27
|
03/06/18
|
2,936
|
34.6519
|
$34.50
|
$34.89
|
03/07/18
|
10,769
|
34.9047
|
$34.50
|
$35.33
|
03/08/18
|
400
|
34.6850
|
$34.50
|
$34.81
|
03/09/18
|
47
|
34.5000
|
$34.50
|
$34.50
|
03/12/18
|
6,761
|
34.5595
|
$34.50
|
$34.89
|
03/13/18
|
12,255
|
35.0308
|
$34.52
|
$35.49
|
03/13/18
|
7,745
|
35.9139
|
$35.54
|
$35.49
|
03/14/18
|
9,189
|
35.3852
|
$34.78
|
$35.77
|
03/14/18
|
2600
|
36.0258
|
$35.79
|
$36.14
|
03/15/18
|
20,000
|
35.4025
|
$34.96
|
$35.95
|
03/16/18
|
15,400
|
35.4134
|
$34.70
|
$35.70
|
03/16/18
|
4,600
|
35.9843
|
$35.73
|
$36.25
|
03/19/18
|
29,059
|
36.3784
|
$35.86
|
$36.86
|
03/19/18
|
466
|
37.0880
|
$36.90
|
$37.60
|
03/19/18
|
500
|
38.056
|
$37.92
|
$38.46
|
03/20/18
|
4,700
|
35.1972
|
$34.84
|
$35.62
|
03/20/18
|
13,636
|
36.1751
|
$35.92
|
$36.50
|
03/21/18
|
3,490
|
34.6079
|
$34.50
|
$35.09
|
03/22/18
|
500
|
34.5320
|
$34.50
|
$34.60
|
04/12/18
|
3,905
|
34.5003
|
$34.50
|
$34.76
|
04/20/18
|
2,700
|
34.5000
|
$34.50
|
$34.50
|
04/23/18
|
3,614
|
32.6157
|
$32.22
|
$32.98
|
04/24/18
|
2,534
|
32.2880
|
$32.00
|
$33.00
|
05/04/18
|
24,384
|
29.1079
|
$29.00
|
$29.40
|
05/04/18
|
8,901
|
29.6576
|
$29.41
|
$30.41
|
05/07/18
|
21,161
|
29.0413
|
$29.00
|
$29.33
|
05/08/18
|
45,554
|
29.0780
|
$29.00
|
$29.30
|
05/09/18
|
50,000
|
30.0009
|
$30.00
|
$30.24
|
05/10/18
|
4,872
|
31.0206
|
$31.00
|
$31.25
|
05/11/18
|
44,468
|
31.0014
|
$31.00
|
$31.24
|
Date
|
Number of Shares of
Common Stock
|
Price per Share*
|
Price Range
|
|
02/05/19
|
10,000
|
26.3426
|
$26.10
|
$26.74
|
02/06/19
|
10,000
|
26.0652
|
$26.00
|
$26.50
|
02/13/19
|
8,583
|
26.0412
|
$26.00
|
$26.10
|
02/14/19
|
800
|
26.0000
|
$26.00
|
$26.00
|
02/15/19
|
10,000
|
26.0464
|
$26.00
|
$26.34
|
02/19/19
|
10,000
|
26.0319
|
$26.00
|
$26.27
|
02/20/19
|
7,647
|
26.0000
|
$26.00
|
$26.00
|
02/22/19
|
10,000
|
26.0174
|
$26.00
|
$26.35
|
02/25/19
|
10,000
|
26.0943
|
$26.00
|
$26.50
|
02/26/19
|
10,000
|
25.9642
|
$25.85
|
$26.51
|
02/26/19
|
2,669
|
27.4354
|
$27.30
|
$27.75
|
02/27/19
|
422
|
26.9170
|
$26.29
|
$27.21
|
02/27/19
|
6200
|
27.4158
|
$27.33
|
$27.53
|
Date: March 13, 2019
|
PHASE4 PARTNERS LIMITED
|
|
By:
|
/s/ Charles Sermon | |
Name: Charles Sermon
|
||
Title: Director
|
||
Date: March 13, 2019
|
PHASE4 VENTURES III LP
|
|
By: Phase4 Partners Limited, its Manager
|
||
By:
|
/s/ Charles Sermon | |
Name: Charles Sermon
|
||
Title Director
|
||
Date: March 13, 2019
|
PHASE4 VENTURES III GP LP
|
|
By: Phase4 Ventures III General Partner Limited,
|
||
its general partner
|
||
By:
|
/s/ Charles Sermon | |
Name: Charles Sermon
|
||
Title Director
|
||
Date: March 13, 2019
|
PHASE4 VENTURES III GENERAL PARTNER
|
|
LIMITED
|
||
By:
|
/s/ Charles Sermon | |
Name: Charles Sermon
|
||
Title Director
|
||
Date: March 13, 2019
|
/s/ Alastair McKinnon | |
Alastair McKinnon
|
||
Date: March 13, 2019
|
/s/ Denise Scots-Knight | |
Denise Scots-Knight
|
||
Date: March 13, 2019
|
/s/ Charles Sermon | |
Charles Sermon
|